Showing results (51-60 of 150) with videos related to

Sort By:
Pageof 15
Biomolecular NMR Assignments|March 9, 2019
Solution NMR assignment of the ARC4 domain of human tankyrase 2Mariola Zaleska, Katie Pollock, Ian Collins, et al.
FEBS Open Bio|June 26, 2025
Phenotypic plasticity in a novel set of EGFR tyrosine kinase inhibitor-adapted non-small cell lung cancer cell linesTharsagini V Nanthaprakash, Campbell W Gourlay, Ina Oehme, et al.
Journal of Medicinal Chemistry|February 16, 2010
Discovery of 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as selective, orally active inhibitors of protein kinase B (Akt)Tatiana McHardy, John J Caldwell, Kwai-Ming Cheung, et al.
Cell Cycle (Georgetown, Tex.)|December 14, 2007
The cyclin-dependent kinase inhibitor seliciclib (R-roscovitine; CYC202) decreases the expression of mitotic control genes and prevents entry into mitosisSteven R Whittaker, Robert H Te Poele, Florence Chan, et al.
The Journal of Biological Chemistry|October 18, 2005
The proto-oncoprotein SYT interacts with SYT-interacting protein/co-activator activator (SIP/CoAA), a human nuclear receptor co-activator with similarity to EWS and TLS/FUS family of proteinsMichela Perani, Per Antonson, Rifat Hamoudi, et al.
Scientific Reports|August 27, 2016
AMPK-independent inhibition of human macrophage ER stress response by AICARMarcel Boß, Yvette Newbatt, Sahil Gupta, et al.
Oncogene|March 1, 2005
Phosphorylation of cyclin D1 at Thr 286 during S phase leads to its proteasomal degradation and allows efficient DNA synthesisYang Guo, Ke Yang, Jyoti Harwalkar, et al.
Chemical Science|November 15, 2021
The phospholipid membrane compositions of bacterial cells, cancer cell lines and biological samples from cancer patientsKira L F Hilton, Chandni Manwani, Jessica E Boles, et al.
Phytochemistry|October 3, 2020
Mechanisms of action for the anti-obesogenic activities of phytochemicalsBilal Ahmad, Emily P Friar, Muhammad Sufyan Vohra, et al.
Molecular Cancer Therapeutics|December 31, 2010
Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930Timothy A Yap, Mike I Walton, Lisa-Jane K Hunter, et al.
Pageof 15